Stroke Stem Cell Therapy Shows Promise
Related News: Spinal / Nervous / BrainStem Cell Therapeutics Corp. (SSS.V) os reporting results from its Phase I pharmacokinetic clinical trial for therapeutic treatment targeting strokes. The drug regimen, NTx-265, consists of two drugs that trigger neural stem cell proliferation.
The study evaluated evidence that these two neural stem cell proliferation inducing drugs did in fact reach the cerebrospinal fluid when administered to human subjects with an intact blood-brain barrier.
The Phase I clinical trial also investigated the pharmacokinetic profile of two of the approved and on market forms of the neural stem cell proliferation inducing drugs.
"The completion of this Phase I clinical trial is an important step for Stem Cell Therapeutics and in the development of the NTx(TM)-265 therapeutic program", said Dr. Joseph Tucker, President & CEO. Dr. Tucker continued, "With this information in hand we feel supported in our decision to move forward with planning a Phase IIa clinical trial, to be conducted in patients suffering from stroke, in the near future".
Stem Cell Therapeutics Corp. Reports Positive Results of Phase I Clinical Trial
Posted on March 17, 2006 12:54 PM